AstraZeneca Q2 Profit Beats Forecasts, Sticks to 2030 Revenue Target Amid Pipeline Push
AstraZeneca Q2 core EPS of $2.63 beat consensus, driven by 15% oncology and 8% rare disease growth. The company maintained its 2030 $80 billion revenue target and has more than 20 Phase III readouts expected over the next 18 months.
AstraZeneca reported second-quarter core earnings of $2.63 per share, beating a company-compiled consensus of $2.48, while total revenue rose 5% to $15.38 billion, roughly in line with expectations of $15.39 billion. The company reaffirmed its annual and long-term forecasts, expressing confidence that recent trial setbacks would not undermine its 2030 ambition of reaching $80 billion in annual revenue.
Oncology sales grew 15% and rare disease sales increased 8%, driving the top-line performance. Revenue from China, the company's second-biggest market, fell 13% due to generic competition and policy changes.
During the quarter, AstraZeneca initiated six Phase III trials for its oral GLP-1 candidate, elecoglipron, in obesity and type 2 diabetes, making it one of the company's largest late-stage programs. More than 20 Phase III readouts are expected over the next 18 months, including two closely watched cancer studies. The company also raised the sales potential for experimental respiratory drug tozorakimab to more than $5 billion, up from a prior estimate of $3 billion.
Recent pipeline setbacks include the nerve drug Wainua and an experimental breast cancer treatment, camizestrant. The CEO commented that biology is not as predictable as mathematics, underscoring the inherent risks of clinical development.
AstraZeneca maintained its 2026 outlook, projecting low double-digit core earnings per share growth and mid-to-high single-digit revenue growth at constant currencies. Finance costs increased due to the Iran war, the finance chief noted without providing specifics.
As of June 21, 2026, AstraZeneca's U.S.-listed shares traded around $174.93. Analyst consensus remains predominantly positive, with average twelve-month price targets implying further upside. The company's key revenue drivers include oncology products such as Tagrisso, Imfinzi, and Enhertu, as well as the cardiovascular drug Farxiga. The U.S. market accounts for nearly half of total revenue, and the company recently upgraded its U.S. listing to the NYSE from NASDAQ ADRs. It also maintains primary listing on the London Stock Exchange and a listing on Nasdaq Stockholm. AstraZeneca has pledged a $50 billion investment in the U.S. by 2030, highlighting the strategic importance of the American market.